About Homeobox protein Meis2
Homeobox protein Meis2 (MEIS2) is a protein
from Homo sapiens identified by UniProt accession
O14770, 477 residues long.
MolForge cross-references it against 0 known binders and
134 disease associations.
Target properties
| Protein name | Homeobox protein Meis2 |
| UniProt accession | O14770 |
| Gene | MEIS2 |
| Organism | Homo sapiens |
| Length | 477 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (134)
Diseases linked to this target (Open Targets).
- cardiac malformation, cleft lip/palate, microcephaly, and digital anomalies · score 0.73
- Cognitive impairment · score 0.53
- genetic disorder · score 0.48
- PHF-tau measurement · score 0.42
- cortical surface area measurement · score 0.41
- waist-hip ratio · score 0.41
- BMI-adjusted waist-hip ratio · score 0.41
- syndromic intellectual disability · score 0.37
- response to risperidone · score 0.34
- brain measurement · score 0.34
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O14770-F1 | alphafold | PREDICTED | 61.96 | — |
Amino-acid sequence (477 residues)
MAQRYDELPH YGGMDGVGVP ASMYGDPHAP RPIPPVHHLN HGPPLHATQH YGAHAPHPNV MPASMGSAVN DALKRDKDAI YGHPLFPLLA LVFEKCELAT CTPREPGVAG GDVCSSDSFN EDIAVFAKQV RAEKPLFSSN PELDNLMIQA IQVLRFHLLE LEKVHELCDN FCHRYISCLK GKMPIDLVID ERDGSSKSDH EELSGSSTNL ADHNPSSWRD HDDATSTHSA GTPGPSSGGH ASQSGDNSSE QGDGLDNSVA SPGTGDDDDP DKDKKRQKKR GIFPKVATNI MRAWLFQHLT HPYPSEEQKK QLAQDTGLTI LQVNNWFINA RRRIVQPMID QSNRAGFLLD PSVSQGAAYS PEGQPMGSFV LDGQQHMGIR PAGLQSMPGD YVSQGGPMGM SMAQPSYTPP QMTPHPTQLR HGPPMHSYLP SHPHHPAMMM HGGPPTHPGM TMSAQSPTML NSVDPNVGGQ VMDIHAQ
Explore Homeobox protein Meis2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets